In this episode Dr. Gillian Beauchamp sits down with Dr. Albert Garcia Romeu to discuss the history of psychedelic use, current treatment protocols and research on using psychedelics to support recovery from substance use disorders. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Michael Twiner and Dr. Brett Johnson to discuss harmful algal blooms (HABs) such as inhalation toxicity from Red Tide, neurotoxic shellfish toxicity, diarrheal shellfish poisoning, and amnestic shellfish toxicity. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Michael Toce to discuss naloxone access laws, increased community availability of naloxone and who still doesn’t have access to naloxone. They also discuss the difference between naloxone and nalmefene and the future of nalmefene. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Kevin Wenzel, PhD to discuss the importance of family involvement including identifying substance use disorder, seeking treatment and providing support during treatment. 

In this episode Dr. Gillian Beauchamp sits down with Jonathan Jarry MSc to discuss trends in health related pseudoscience and our role in fighting misinformation. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Andrew Stolbach to discuss the mechanishm of action,  toxicity and management of checkpoint inhibitors (immunotherapeutic agents used in the treatment of cancer).

In this episode Dr. Gillian Beauchamp sits down with Dr. Joshua Trebach to discuss the benefits and drawbacks of utilizing social media to increase awareness and promote medical toxicology. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Filza Hussain to discuss transplant organ allocation in patients who have organ failure secondary to a suicide attempt. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Matthew Salzman discusses the complications associated with the use of illicit fentanyl containing xylazine from wounds to withdrawal. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Alan Wolfe to discuss the possible clinical effects of  POPs (Persistent Organic Pollutants) and PFAS (Per and polyfluoroalkyl substances).